Navigation Links
AstraZeneca Pays $520 Million to Settle Seroquel Whistleblower Claims
Date:4/28/2010

Kenney & McCafferty Represent Whistleblower Dr. Stefan Kruszewski

(PRWEB) April 28, 2010 -- AstraZeneca has agreed to pay $520 million in civil fines, penalties and damages to settle allegations that the company defrauded Medicare, Medicaid and other government-funded health care programs in connection with its marketing and promotional practices for the blockbuster atypical antipsychotic Seroquel (U.S. ex rel. STEFAN KRUSZEWSKI, MD v. ASTRAZENECA PHARMACEUTICALS, LP., Eastern District of Pennsylvania, C.A. No. 06-4004.). This is the largest settlement of off-label marketing claims brought under the False Claims Act to date that involved civil-only fines. The $520 million settlement resolves a qui tam lawsuit filed by whistleblower Dr. Stefan Kruszewski, one of two relators to file a case. Dr. Kruszewski was represented by Brian Kenney and Tavy Deming of the Kenney & McCafferty law firm, along with William Leonard of Obermayer, Rebmann, Maxwell & Hippel.

Seroquel, a potent atypical antipsychotic, was FDA-approved only for two narrow uses in adults, schizophrenia and manic episodes associated with bipolar I disorder, at the time that Dr. Kruszewski filed his complaint. Harvard-trained psychiatrist Dr. Kruszewski alleged, however, that AstraZeneca engaged in an egregious, long term off-label marketing scheme by specifically targeting children and the elderly when those uses were never properly tested or approved by the FDA and that AstraZeneca marketed the drug for a litany of off-label uses, including depression, anxiety, ADHD and insomnia.

Dr. Kruszewski's complaint further alleged that AstraZeneca arranged for clinical trials that embellished efficacy data and also downplayed the drug’s serious side effects. Dr. Kruszewski alleged that AstraZeneca used these studies to stifle physician concerns about the drug's serious treatment-emergent side effects, including type II diabetes, hyperglycemia, cardiovascular complications, heart attacks, stroke, and, in some cases, an increase in the risk of mortality.

“The manipulation and misuse of Seroquel scientific data to support AstraZeneca’s off-label marketing campaign was the most disturbing aspect of the case to me,” Dr. Kruszewski said. “There were strong indications from AstraZeneca’s earliest clinical trials that Seroquel increased the risk of diabetes and induced profound sedation out of proportion to its weak antipsychotic effects.”

Kruszewski added that “rather than properly warning doctors and the public, AstraZeneca intentionally covered up the evidence on diabetes and other serious side effects and used the sedative property of Seroquel as a selling point.” “In the elderly population, they basically marketed Seroquel as an expensive sleeping pill and put hundreds of thousands of patients at risk for serious medical complications, premature cardiovascular disease, pneumonias, and premature death.”

“This was a well thought out marketing campaign that operated on many levels,” stated Brian Kenney. “AstraZeneca orchestrated scientific studies, ghost written articles, and the payment of large fees to academic psychiatrists to act as ‘thought leaders’ to promote the drug off label. The success can be seen in the huge numbers the campaign generated with 4.9 billion in sales in 2009.” “It’s particularly disconcerting that AstraZeneca successfully co-opted large portions of psychiatric academic community,” added Mr. Kenney.

“From the outset of this case, Dr. Kruszewski was passionate about bringing to light AstraZeneca’s concealment of unfavorable Seroquel studies as well as the company’s’ improper use of what he deemed to be flawed scientific studies to promote the drug off label,” said Tavy Deming.

The U.S. Attorney's Office for the Eastern District of Pennsylvania conducted the federal investigation into AstraZeneca's Seroquel marketing practices under the direction of U.S. Attorney Michael Levy, Assistant U.S. Attorneys Virginia Gibson and Colin Cherico.

U.S. ex rel. STEFAN KRUSZEWSKI, MD v. ASTRAZENECA PHARMACEUTICALS, LP., Eastern District of Pennsylvania, C.A. No. 06-4004.

Call Tavy Deming or Brian P. Kenney at 610-940-0327 to arrange availability for the complete news release or other public material related to the case.

About Kenney & McCafferty, P.C. (http://www.quitam-lawyer.com)

Kenney & McCafferty ("K&M") specializes in qui tam and tax whistleblower litigation. K&M represents whistleblowers nationwide and has recovered more than $4 billion for the government in False Claims Act and tax whistleblower cases. Recent K&M pharmaceutical False Claims Act settlements include Pfizer, Inc./Geodon; Eli Lilly/Zyprexa; and Cephalon, Inc./Actiq, Provigil and Gabitril..

Brian P. Kenney, Esq.
Tavy Deming, Esq.
Kenney & McCafferty, P.C.
3031C Walton Road, Suite 202
Plymouth Meeting, PA 19462
610-940-0327
www.quitam-lawyer.com

###

Read the full story at http://www.prweb.com/releases/2010/04/prweb3937374.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related medicine news :

1. Angel.com Launches Caller First IVR Solutions with AstraZeneca
2. PharmaSmart International, Inc and AstraZeneca Canada Enter Into Strategic Partnership to Elevate Pharmacy Based Hypertension Management
3. Freedland Russo Announces $520 Million Settlement Against AstraZeneca
4. Kaiser Permanente Gives $5 Million to Childrens Healthcare of Atlanta
5. RadioShack Customers Donate $1.3 Million to LIVESTRONG
6. Michael J. Fox Foundation Awards $2.8 Million to Drive Development of Parkinsons Disease Biomarker Pipeline
7. Human Rights Denied: Obama Leaves 75 Million Children Behind
8. NVHR: Administrations 2011 Budget Proposal Shortchanges Five Million Americans Afflicted with Chronic Viral Hepatitis
9. State $200 Million Behind in Payments to Agencies Providing Care to Thousands of Older Illinoisans
10. Prominent Beverly Hills Law Firm Awarded $16.5 Million Medical Malpractice Jury Verdict
11. Esperanza Health Center Receives $6.5 Million in Stimulus Funds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... Cirracore Enterprise Cloud, today announced ... to the cloud. Cirracore provides a secure VMware® vCloud Air based cloud ... Transformation Solutions (TSL Partners) provides a full range of services from planning, ...
(Date:2/9/2016)... Springs, FL (PRWEB) , ... February 09, 2016 ... ... leading innovative specialty pharmacies, announces today the continuation of the ‘Pay It Forward’ ... for each prescription referral received at our specialty pharmacy. , “Since our ...
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... On January ... family scheduled an appointment after they noticed their furnace not producing any heat. Shortly ... heat exchanger. The cracked heat exchanger was leaking dangerous levels of carbon monoxide into ...
(Date:2/9/2016)... ... February 09, 2016 , ... The Bon-Ton Stores, Inc. (NASDAQ: ... stores, announced it has raised $176,000 to benefit the Breast Cancer Research Foundation, ... at the University of Iowa, The Lynn Sage Cancer Research Foundation, and Masonic ...
(Date:2/9/2016)... ... February 09, 2016 , ... ZipHearing.com is ... to affordable hearing aids , increase industry transparency, and promote awareness of ... States. , “For the average consumer, the hearing aid industry is esoteric and ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... N.Y., Feb. 9, 2016  Misonix, Inc. (NASDAQ: ... that designs, manufactures and markets innovative therapeutic ultrasonic ... debridement, cosmetic surgery, laparoscopic surgery and other surgical ... quarter and the first half of fiscal year ... --> --> Highlights for ...
(Date:2/9/2016)... -- Insulet Corporation (NASDAQ: PODD ) (Insulet or the Company), ... its OmniPod ® Insulin Management System, today ... to Insulet,s Board of Directors. With his appointment, the Board ... independent. --> --> Mr. ... and a deep knowledge of accounting, financial reporting and internal ...
(Date:2/9/2016)...  Sangamo BioSciences, Inc. (NASDAQ: SGMO ), ... its fourth quarter and full year 2015 financial ... therapeutic genome editing," said Edward Lanphier, Sangamo,s president ... (ZFN) technology leads the therapeutic genome editing field ... to move our ground-breaking genome editing programs through ...
Breaking Medicine Technology: